PCSK9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: a systematic review and meta-analysis

Back

ESC Professional Premium Access

PCSK9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: a systematic review and meta-analysis

Session: Risk factors and prevention: lipids (1)

Topic: Drug therapy

Speaker: Mr A. Khan (Providence, US)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Mr Ali Khan

Brown University, Providence (United States of America)

0 follower

7 more presentations in this session

Severe hypertriglyceridemia and its correlation with clinical atherosclerosis and pancreatitis investigated in beta-quantification

Speaker: Associate Professor Y. Winhofer (Vienna, AT)

Comparison of estimated LDL cholesterol equations with direct measurement

Speaker: Mr G. Velisaris (Athens, GR)

The Cycle study: a prospective study on cholesterol levels during the menstrual cycle

Speaker: Miss J. Mulder (Rotterdam, NL)

Low-density lipoprotein cholesterol reduction and short-term incidence of ASCVD in the population-based cohort study LATINO

Speaker: Professor C. Gavina (Porto, PT)

Association of statin use and outcomes in elderly with multiple risk factors: insight from the CORE registry Thailand.

Speaker: Doctor P. Chichareon (Hat Yai, TH)

Access the full session

Risk factors and prevention: lipids (1)

Speakers: Mr A. Khan, Associate Professor Y. Winhofer, Mr G. Velisaris, Miss J. Mulder, Professor C. Gavina...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources